Medicare Enrolled
Dr. Daniel Sugai, M.D.
Internal Medicine · Bellevue, WA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Sugai from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Sugai?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Sugai
Dr. Daniel Sugai is an internal medicine specialist in Bellevue, WA, with 14 years of NPI registration. Based on federal Medicare data, Dr. Sugai performed 6,374 Medicare services across 2,441 unique beneficiaries.
Between the years covered by Open Payments, Dr. Sugai received a total of $249,790 from 45 pharmaceutical and/or device companies across 1185 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in internal medicine. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Sugai is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 14 years in practice
▲ Top 1% volume in WA
$249,790 industry payments
Medicare Practice Summary
Medicare Utilization ↗6,374
Medicare services
Top 1% in WA for internal medicine
2,441
Unique beneficiaries
$43
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~455 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Destruction of precancerous skin growths, 2-14 This procedure involves the removal or destruction of two to fourteen precancerous skin lesions. It is performed to eliminate abnormal skin cells that have the potential to develop into cancer. |
3,357 | $6 | $20 |
| Destruction of precancerous skin growth, 1 Removal of a single precancerous skin growth. This procedure destroys abnormal skin cells to prevent them from developing into cancer. |
711 | $42 | $220 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
527 | $67 | $246 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
452 | $98 | $358 |
| Destruction of skin growths (warts/lesions), 1-14 This procedure involves the removal or destruction of one to fourteen skin growths. It is a minor surgical intervention performed on the skin surface. |
349 | $100 | $377 |
| Skin biopsy, tangential A procedure to remove a sample of the first identified skin growth for laboratory examination. |
317 | $72 | $338 |
| Destruction of 15 or more precancerous skin growths This procedure involves the removal or destruction of fifteen or more precancerous skin lesions. It is performed to treat abnormal skin cells that have the potential to develop into cancer. |
134 | $148 | $513 |
| Additional skin growth biopsy Removal of a sample of an additional skin growth for laboratory examination. This code is used for each extra lesion biopsied during the same session. |
112 | $45 | $182 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
70 | $41 | $152 |
| Complicated wound repair, scalp/arms/legs, 2.6-7.5 cm A complex surgical procedure to close a wound on the scalp, arms, or legs that measures between 2.6 and 7.5 centimeters in length. |
57 | $373 | $1,455 |
| Surgical removal of skin cancer, 2.1-3.0 cm This procedure involves the surgical excision of a cancerous skin growth located on the body, arms, or legs. The size of the removed tissue measures between 2.1 and 3.0 centimeters. |
50 | $129 | $954 |
| Surgical removal of skin cancer, 1.1-2.0 cm Surgical excision of a cancerous skin growth measuring between 1.1 and 2.0 centimeters on the body, arms, or legs. |
42 | $111 | $839 |
| Complicated wound repair of trunk, 2.6-7.5 cm A surgical procedure to close a complex wound on the trunk that measures between 2.6 and 7.5 centimeters in length. |
41 | $350 | $1,355 |
| Steroid injection (triamcinolone) A 10 mg injection of triamcinolone acetonide, a corticosteroid medication. This code specifies the drug and dosage administered. |
37 | $1 | $14 |
| Injection into skin growths, 1-7 A procedure involving the injection of medication into one to seven skin growths. |
34 | $33 | $184 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
29 | $67 | $357 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
25 | $115 | $538 |
| Destruction of cancer skin growth, 1.1-2.0 cm Removal of a cancerous skin growth on the trunk, arms, or legs that measures between 1.1 and 2.0 centimeters. |
18 | $138 | $596 |
| Ear tissue biopsy A procedure to remove a small sample of tissue from the ear for laboratory examination. |
12 | $65 | $334 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$249,790
Total received (2018-2024)
Avg $35,684/year across 7 years
Top 1% in WA for internal medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
45
Companies
1,185
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$180,170 (72.1%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$49,868 (20.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$19,752 (7.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$191,886
2023
$29,491
2022
$19,598
2021
$2,822
2020
$1,626
2019
$2,786
2018
$1,580
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Galderma Laboratories, L.P.
$138,267
Amgen Inc.
$48,079
E.R. Squibb & Sons, L.L.C.
$1,789
Janssen Biotech, Inc.
$661
SUN PHARMACEUTICAL INDUSTRIES INC.
$445
Regeneron Healthcare Solutions, Inc.
$430
ABBVIE INC.
$408
GENZYME CORPORATION
$345
UCB, Inc.
$343
PFIZER INC.
$241
Incyte Corporation
$208
Novartis Pharmaceuticals Corporation
$174
Arcutis Biotherapeutics, Inc.
$161
Lilly USA, LLC
$150
Dermavant Sciences, Inc.
$65
Organon Llc
$39
Biofrontera Inc.
$39
Janssen Scientific Affairs, LLC
$15
Ortho Dermatologics, a division of Bausch Health US, LLC
$14
Helsinn Therapeutics (U.S.), Inc.
$14
Top 3 companies account for 98.0% of 2024 payments
All-time payments by company (2018-2024) ›
Galderma Laboratories, L.P.
$180,835
Amgen Inc.
$48,717
Janssen Biotech, Inc.
$2,443
E.R. Squibb & Sons, L.L.C.
$2,140
Novartis Pharmaceuticals Corporation
$1,773
AbbVie Inc.
$1,266
Arcutis Biotherapeutics, Inc.
$1,136
ABBVIE INC.
$1,089
UCB, Inc.
$1,069
GENZYME CORPORATION
$986
PFIZER INC.
$983
Regeneron Healthcare Solutions, Inc.
$918
Lilly USA, LLC
$902
Incyte Corporation
$668
Biofrontera Inc.
$642
Ortho Dermatologics, a division of Bausch Health US, LLC
$598
Mayne Pharma Inc.
$509
AbbVie, Inc.
$493
Sun Pharmaceutical Industries Inc.
$471
SUN PHARMACEUTICAL INDUSTRIES INC.
$445
LEO Pharma Inc.
$345
Dermavant Sciences, Inc.
$265
Almirall LLC
$162
Celgene Corporation
$134
VYNE Pharmaceuticals Inc.
$98
Sandoz Inc.
$94
Helsinn Therapeutics (U.S.), Inc.
$70
Boehringer Ingelheim Pharmaceuticals, Inc.
$58
Organogenesis Inc.
$56
ORGANOGENESIS INC.
$49
PruGen, Inc. Pharmaceuticals
$39
Organon Llc
$39
Bayer HealthCare Pharmaceuticals Inc.
$35
MAYNE PHARMA INC.
$33
Organon LLC
$32
Phadia US Inc.
$30
DERMIRA, INC.
$28
Merz North America, Inc.
$26
TARO PHARMACEUTICALS USA, INC.
$21
DUSA Pharmaceuticals, Inc.
$17
Promius Pharma LLC
$17
Merck Sharp & Dohme Corporation
$16
Mylan Pharmaceuticals Inc.
$15
Janssen Scientific Affairs, LLC
$15
Mission Pharmacal Company
$14
Top 3 companies account for 92.9% of all-time payments
Associated products mentioned in payments ›
ADBRY · AKLIEF · ALTRENO · AMELUZ · AMZEEQ · ARAZLO · Absorica LD · Ameluz · Bimzelx · CIBINQO · COSENTYX · Cimzia · Cloderm Cream · Cordran Tape · DERMATITIS - DISEASE · DORYX · DUOBRII · DUPIXENT · DUPIXENT DUPILUMAB INJECTION · ELIDEL · ENSTILAR · EPIDUO FORTE · EUCRISA · FINACEA · Finacea · HADLIMA · HUMIRA · HYRIMOZ · Humira · ILUMYA · ILUMYA (tildrakizumab-asmn) injection · ImmunoCAP · JUBLIA · JUBLIA EFINACONAZOLE · KERYDIN · Klisyri · LEXETTE · LIBTAYO · LITFULO · ODOMZO · OLUMIANT · ONEXTON · OPZELURA · ORACEA · Odomzo · Olux · Otezla · Ovace · Puraply · Puraply Antimicrobial · QBREXZA · REMICADE · RETIN-A MICRO · RETIN-A-MICRO · RINVOQ · SILIQ · SIVEXTRO · SKYRIZI · SOOLANTRA · SPEVIGO · Seysara · Skyrizi · Sotyktu · TALTZ · TREMFYA · TWYNEO · Tremfya · ULTRAVATE · VALCHLOR · VTAMA · Winlevi · ZILXI · Zoryve
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (72%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in internal medicine and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for internal medicine in WA.
Geographic Context
Internal medicine physicians within 10 mi
2,037
Per 100K population
90.0
County median income
$122,148
Nearest hospital
OVERLAKE HOSPITAL MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Sugai is a clinical cardiology specialist, with above-average Medicare volume (top 1% in WA), with speaking/promotional industry engagement in the top 1% of WA peers.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Sugai experienced with destruction of precancerous skin growths, 2-14?
Based on Medicare claims data, Dr. Sugai performed 3,357 destruction of precancerous skin growths, 2-14 services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Sugai receive payments from pharmaceutical companies?
Yes. Dr. Sugai received a total of $249,790 from 45 companies across 1,185 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Sugai's costs compare to other internal medicine physicians in Bellevue?
Dr. Sugai's average Medicare payment per service is $43. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Sugai) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Internal Medicine Physicians in Bellevue
Browse internal medicine physicians in Bellevue ranked by procedure volume and transparency data.
Highest volume
Top Internal Medicine Physicians in WA
Internal medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Internal Medicine Physicians in WA
Which WA internal medicine physicians receive the most from drug and device companies.
By company
Galderma Laboratories, L.P. Payments to Doctors
See all physicians who received payments from Galderma Laboratories, L.P.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology